Anorectal mucosal melanoma

Giulia Malaguarnera _, Roberto Madeddu, Vito Emanuele Catania, Gaetano Bertino, Luca Morelli, Rosario Emanuele Perrotta, Filippo Drago, Michele Malaguarnera and Saverio Latteri

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:8785-8800. https://doi.org/10.18632/oncotarget.23835

Metrics: PDF 2357 views  |   HTML 4093 views  |   ?  


Giulia Malaguarnera1,7, Roberto Madeddu2, Vito Emanuele Catania3, Gaetano Bertino4, Luca Morelli5, Rosario Emanuele Perrotta6, Filippo Drago7, Michele Malaguarnera1,7 and Saverio Latteri3

1Research Center “The Great Senescence”, University of Catania, Catania, Italy

2Department of Biomedical Sciences, University of Sassari, Sassari, Italy

3Department of Medical, Surgical Sciences and Advanced Technologies “G.F. Ingrassia”, University of Catania, Catania, Italy

4Hepatology Unit, Department of Clinical and Experimental Medicine, University of Catania, Policlinico “G. Rodolico”, Catania, Italy

5Department of Surgery, University of Pisa, Pisa, Italy

6Department of General Surgery and Medical-Surgery Specialties, University of Catania, Catania, Italy

7Department of Biomedical and Biotechnological Science, University of Catania, Catania, Italy

Correspondence to:

Giulia Malaguarnera, email: [email protected]

Keywords: malignant melanoma; mucosal melanoma; anorectal tumours; anorectal melanoma; treatment

Received: August 07, 2017     Accepted: December 26, 2017     Published: January 02, 2018


Anorectal melanoma is an uncommon and aggressive mucosal melanocytic malignancy. Due to its rarity, the pre-operative diagnosis remains difficult. The first symptoms are non-specific such as anal bleeding, anal mass or pain. Although anorectal melanoma carries a poor prognosis; optimal therapeutics strategies are unclear.

Surgical resection remains the mainstay of treatment. The optimal surgical procedure for primary tumours is controversial and can vary from wide local excision or endoscopic mucosal resection (EMR) to an abdomino-perineal resection.

A high degree of uncertainly exists regarding the benefit of radiation therapy or chemotherapy. The treatment of advanced melanoma is evolving rapidly with better understanding of the disease biology and immunology. Considerable effort has been devoted to the identification of molecular determinants of response to target therapies and immunotherapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23835